OSTENT

Novel Materials and Processing Strategy for Oesophageal Stents

 Coordinatore FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG 

 Organization address address: SCHLOSSPLATZ 4
city: ERLANGEN
postcode: 91054

contact info
Titolo: Mrs.
Nome: Ulrike
Cognome: Hoffmann
Email: send email
Telefono: +49 9131 85 24043
Fax: +49 9131 85 26239

 Nazionalità Coordinatore Germany [DE]
 Totale costo 216˙952 €
 EC contributo 216˙952 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-IEF
 Funding Scheme MC-IEF
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-08-01   -   2016-08-01

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG

 Organization address address: SCHLOSSPLATZ 4
city: ERLANGEN
postcode: 91054

contact info
Titolo: Mrs.
Nome: Ulrike
Cognome: Hoffmann
Email: send email
Telefono: +49 9131 85 24043
Fax: +49 9131 85 26239

DE (ERLANGEN) coordinator 216˙952.80

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

device    cancer    creation    stent    therapeutic    oesophageal    biomaterials    treatment    stents    palliative   

 Obiettivo del progetto (Objective)

'There is a need for addressing the condition and symptoms associated with oesophageal cancer in Europe and Worldwide. Around 5-10 in every 1000 men and around 1 in every 1000 women will develop oesophageal cancer during their lifetime, with care being mainly palliative via oesophageal stents, rather than therapeutic. This form of cancer has been demonstrated to be on the increase in Europe due to the growth in cases of adenocarcinomas, which in turn can be linked to the increase in alcohol consumption and obesity in western countries.

There are problems associated with the current palliative treatments available for oesophageal cancer. Namely, tumour ingrowth into the stent, hyperplasic tissue formation and migration of the device. In the past few years, the scientific development of oesophageal stents has been on an increase However, the creation of a therapeutic device rather than merely a palliative one is still unavailable. Such an advancement would cause a major shift in the treatment of oesophageal cancer, allowing the state of the art to be pushed into new realms.

This proposal will address the ultimate goal of treating the condition of oesophageal cancer with the aim of restoring oesophageal function and returning the lives of sufferers to near-normal states. This will be achieved by the creation of a novel drug-eluting, shape memory, degradable composite stent using the experience of the researcher (Dr Judith Juhasz) and supervisor (Professor Aldo Boccaccini) at the Institute of Biomaterials in the University of Erlangen-Nuremberg, Germany. Creation of this novel material within this Marie Curie Intra-European Fellowship will advance the understanding of stent design for the treatment of oesophageal cancer and will put Europe in a leading position as a competitor in the biomaterials market.'

Altri progetti dello stesso programma (FP7-PEOPLE)

HEURECA 2012 (2012)

A Hungarian Night for Researchers 2011- Hungary-EU Research Careers

Read More  

TARGEAR (2014)

Targeting challenges of active ageing: innovative integrated strategies for the healing of age-related hearing loss

Read More  

FRZDMD (2012)

Contribution of calcium-independent isoforms of phospholipase A2 in the pathogenesis of Duchenne muscular dystrophy

Read More